Theseus Pharmaceuticals (THRX) Stock Price, News & Analysis

Company Overview

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Key Stats

• Today's Range: $4.06 to $4.06
• 50-Day Range: $4.06 to $4.07
• 52-Week Range: $2.05 to $12.37
• Volume: N/A
• Average Volume: 592,167 shs
• Market Capitalization: $179.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

THRX Stock Analysis - Frequently Asked Questions

How were Theseus Pharmaceuticals' earnings last quarter?

Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) issued its earnings results on Monday, November, 15th. The company reported ($5.16) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by $4.93.

When did Theseus Pharmaceuticals IPO?

Theseus Pharmaceuticals (THRX) raised $150 million in an IPO on Thursday, October 7th 2021. The company issued 10,000,200 shares at $14.00-$16.00 per share.

What other stocks do shareholders of Theseus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Theseus Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Visa (V) and Home Depot (HD).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 7/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:THRX
• CIK: 1745020
• Web: theseusrx.com
• Phone: 857-400-9491
• Fax: N/A
• Employees: 38
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$50.61 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -24.84%
• Return on Assets: -23.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 29.93
• Quick Ratio: 29.93

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.36 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 44,230,000
• Free Float: 23,575,000
• Market Cap: $179.57 million
• Optionable: Optionable
• Beta: 3.98